Skip to main content
Clinical Trials/NCT00399204
NCT00399204
Withdrawn
Phase 4

A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes

Post Graduate Institute of Medical Education and Research, Chandigarh1 site in 1 countryJanuary 2006

Overview

Phase
Phase 4
Intervention
Pioglitazone vs Metformin
Conditions
Type 2 Diabetes
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Locations
1
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
December 2012
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Responsible Party
Principal Investigator
Principal Investigator

SHotra

professor

Post Graduate Institute of Medical Education and Research, Chandigarh

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years.
  • Ready to give written informed consent

Exclusion Criteria

  • Presence of ketonuria
  • Severe concurrent, infection or illness
  • History of hypersensitivity to any study drug
  • Impaired renal function
  • Pulmonary insufficiency with hypoxemia
  • Severe hepatic disease
  • Congestive heart failure
  • History of myocardial infarction or angina(stable/unstable)
  • History of alcohol or drug abuse
  • Pregnant or lactating women -

Arms & Interventions

Control

Metformin

Intervention: Pioglitazone vs Metformin

Experimental

Pioglitazone

Intervention: Pioglitazone vs Metformin

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials